Built from weaker models, sales multiples or analyst targets, so treat it as a rough guide.
Not used by alerts or posts.
Valued as a loss-making company: Sales comps and Analyst consensus.
ACCE opinionMannatech Incorporated Common Stock (MTEX)
Fair value
Not available
ACCE price target
$6.30
Rating
Not rated
Horizon
12 months
ACCE price target published on 15 Oct 2026, 00:00 CEST.
Price used: $8.43 at the close on 23 Oct 2026, 22:00 CEST.
Models: Analyst consensus and Sales comps.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
ACCE score
58
out of 100
1-year return
-9.9%
Dividend yield
0.00%
Mannatech Incorporated Common Stock in four questions
Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
Overview
ACCE thesis
Mannatech sells nutritional supplements, weight-management products and skincare through a network of independent distributors, with much of its volume coming from multi-level marketing sales. The stock screens cheaply on forward earnings at 9.6 times, with revenue growing 3.8% and an operating margin of 3.8% on a 76.1% gross margin, a combination that points to a business with high product markups but thin profit after distributor compensation. The negative return on equity of -1490.1% reflects a very small equity base rather than deteriorating operations, so the balance sheet needs a direct look before anything else. At a 14 million dollar market cap with no index membership, the name sits well below the coverage and liquidity threshold most portfolios require, which is why it deserves a deeper look only if the team is comfortable with distributor-network regulatory risk and the durability of a shrinking-equity, modestly growing top line.
⚠ Investor warnings · 4 flagsAI-assisted·How I use AI
severe
Negative equity and cash burn
Debt/Equity of -1.41 and free cash flow of $-4,316,000 on a $16M market cap signal a fragile capital structure. Return on equity of -1490.1% reflects a shrinking equity base.
high
Long-term revenue decline
Five-year revenue CAGR of -6.5% contrasts with the recent +3.8% YoY uptick. One year of growth does not reverse the multi-year trend.
moderate
Price well above ACCE target
The stock trades 33.8% above the ACCE price target of $6.30 against a price of $8.43. The gap is a valuation caution, not a forecast.
moderate
Thin float and insider control
Insiders hold 59.3% and institutions 15.1%, leaving a small free float in a $16M company. Liquidity can be poor and price moves can be exaggerated.
AI research notes
AI-assisted·How I use AIWritten Oct 23, 2026 · figures from 2026-06-30 · prices to Oct 23, 2026
Why it could do well
Revenue grew 3.8% year over year in the latest 10-Q, after several years of decline.
Analysts' mean price target of $20.00 sits well above the current $8.43 share price.
The diluted share count rose only 0.8% last fiscal year, so shareholders are not being heavily diluted.
Why it could disappoint
Free cash flow over the last twelve months was negative at -$4M, so the business is consuming cash.
Return on equity of -1490.1% and debt to equity of -1.41 point to negative shareholder equity, a serious balance sheet concern.
The shares trade 33.8% above the ACCE price target of $6.30, leaving little margin for error.
Each chip shows the exact figure and where it comes from. A claim without a source is not published.
Next results
Nov 11, 2026
We update the fair value about 2 days after the results, once the new figures are filed.Add to calendarGoogle
Walk me through this stock
Plain-English pros, cons, and what to watch. Pro feature.
PRO
Ask ACCE
Valuation
INVESTOR
Where MTEX's valuation models land
Price
$8.43
Model fair valueConfidence: low
about $31.37
Model
Fair value
Upside
Analyst consensus
Sales comps
Create a free account: 5 full stock pages a month, no card.
See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.
Quality
INVESTOR
Quality and conviction INVESTOR FEATURE
The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.
+A plain reason under every score
+Conviction breakdown and growth / value / quality / momentum scores
+Score history: how each score moved over time
Analysts
Wall Street consensus
No analyst coverage yet.
Analyst intelligence INVESTOR FEATURE
The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.
+Price-target low / average / high vs the current price, with implied upside
+Forward revenue and EPS consensus by fiscal year
+ACCE fair-value models lined up against the Street
Smart Money
PRO
In one line
Trades are only made public after a delay. We show the delay so you know how old the news is.